Harmony Biosciences Stock (NASDAQ:HRMY)
Previous Close
$32.48
52W Range
$27.97 - $41.61
50D Avg
$35.90
200D Avg
$32.94
Market Cap
$1.87B
Avg Vol (3M)
$722.60K
Beta
0.77
Div Yield
-
HRMY Company Profile
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
HRMY Performance
Peer Comparison
| Ticker | Company |
|---|---|
| PLRX | Pliant Therapeutics, Inc. |
| NUVL | Nuvalent, Inc. |
| GOSS | Gossamer Bio, Inc. |
| IDYA | IDEAYA Biosciences, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| VRDN | Viridian Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| VTYX | Ventyx Biosciences, Inc. |
| CERE | Cerevel Therapeutics Holdings, Inc. |
| TVTX | Travere Therapeutics, Inc. |
| FENC | Fennec Pharmaceuticals Inc. |
| REPL | Replimune Group, Inc. |
| SNDX | Syndax Pharmaceuticals, Inc. |
| JANX | Janux Therapeutics, Inc. |
| KRON | Kronos Bio, Inc. |
| INZY | Inozyme Pharma, Inc. |
| KROS | Keros Therapeutics, Inc. |
| GPCR | Structure Therapeutics Inc. |
| PTGX | Protagonist Therapeutics, Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| NVCT | Nuvectis Pharma, Inc. |
| VRNA | Verona Pharma plc |